| Ytd | 84.80% | |
| 1y | 155.19% |
| Open | 43.46 | Prev Close | 43.78 | Low | 42.68 | High | 43.76 | Mkt Cap | 2.13B |
| Vol | 168.89K | Avg Vol | 814.60K | EPS | -2.75 | P/E | -15.92 | Forward P/E | 31.35 |
| Beta | 1.56 | Short Ratio | 9.27 | Inst. Own | 101.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 32.94 | 200-d Avg | 24.13 | 1yr Est | 41.63 |
URGN News
UroGen Pharma is shifting NMIBC treatment from surgery to office-based chemoablative therapy with ZU
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing inno
PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, to
The IND clearance enables initiation of a planned Phase 1 clinical study in patients with non-muscle
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical a
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's fi
10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $
5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weight
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tr
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's int
PRINCETON, N. J. , June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnol
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent B
PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Co
From a technical perspective, Urogen Pharma (URGN) is looking like an interesting pick, as it just r
UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, refle
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
On Thursday, 147 companies achieved new lows for the year.
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report
Stocks That Hit 52-Week Lows On Monday